Loading...

NeuroSearch

DB:NRS
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NRS
DB
DKK108M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NeuroSearch A/S does not have significant operations. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
NRS Share Price and Events
7 Day Returns
0%
DB:NRS
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
40.1%
DB:NRS
-10.6%
DE Biotechs
-6.2%
DE Market
NRS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NeuroSearch (NRS) 0% 0% -0.7% 40.1% 81.3% 23.4%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • NRS outperformed the Biotechs industry which returned -10.6% over the past year.
  • NRS outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
NRS
Industry
5yr Volatility vs Market

Value

 Is NeuroSearch undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NeuroSearch. This is due to cash flow or dividend data being unavailable. The share price is €0.58.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NeuroSearch's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NeuroSearch's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NRS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in DKK DKK-0.12
CPSE:NEUR Share Price ** CPSE (2019-04-18) in DKK DKK4.44
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NeuroSearch.

DB:NRS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:NEUR Share Price ÷ EPS (both in DKK)

= 4.44 ÷ -0.12

-38.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroSearch is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NeuroSearch is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NeuroSearch's expected growth come at a high price?
Raw Data
DB:NRS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -38.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NeuroSearch, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NeuroSearch's assets?
Raw Data
DB:NRS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in DKK DKK2.90
CPSE:NEUR Share Price * CPSE (2019-04-18) in DKK DKK4.44
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:NRS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:NEUR Share Price ÷ Book Value per Share (both in DKK)

= 4.44 ÷ 2.90

1.53x

* Primary Listing of NeuroSearch.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroSearch is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NeuroSearch's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NeuroSearch has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NeuroSearch expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroSearch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NeuroSearch expected to grow at an attractive rate?
  • Unable to compare NeuroSearch's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NeuroSearch's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare NeuroSearch's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:NRS Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NRS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NRS Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2018-12-31 -2 -3
2018-06-30 0 -11
2018-03-31 -2 -11
2017-12-31 -5 -11
2017-06-30 -17 21
2017-03-31 -13 21
2016-12-31 -9 22
2016-09-30 -3 8
2016-06-30 -2 -6
2016-03-31 -4 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NeuroSearch is high growth as no earnings estimate data is available.
  • Unable to determine if NeuroSearch is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NRS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from NeuroSearch Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NRS Past Financials Data
Date (Data in DKK Millions) EPS *
2018-12-31 -0.12
2018-06-30 -0.46
2018-03-31 -0.45
2017-12-31 -0.44
2017-06-30 0.85
2017-03-31 0.86
2016-12-31 0.88
2016-09-30 0.33
2016-06-30 -0.22
2016-03-31 -0.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NeuroSearch will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine NeuroSearch's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. NeuroSearch's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. NeuroSearch's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess NeuroSearch's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NeuroSearch has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NeuroSearch performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NeuroSearch's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NeuroSearch does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare NeuroSearch's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NeuroSearch's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NeuroSearch's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NeuroSearch Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NRS Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -2.84 5.30
2018-06-30 -11.35 3.70
2018-03-31 -11.10 3.45
2017-12-31 -10.85 3.20
2017-06-30 20.82 7.23
2017-03-31 21.22 7.43
2016-12-31 21.62 7.63
2016-09-30 8.05 6.91
2016-06-30 -5.51 6.19
2016-03-31 -6.16 6.34
2015-12-31 -6.81 6.49
2015-06-30 -6.21 6.47
2015-03-31 -7.76 9.87
2014-12-31 -9.31 13.27
2014-06-30 -14.93 19.18 1.79
2014-03-31 9.82 18.18 13.49
2013-12-31 -3.23 16.68 21.69
2013-09-30 150.19 17.33 41.96
2013-06-30 138.79 12.63 53.76
2013-03-31 120.72 -321.91 12.23 60.26
2012-12-31 -332.91 11.93 71.06
2012-09-30 -538.18 -74.09 81.23
2012-06-30 -747.68 24.21 240.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NeuroSearch has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NeuroSearch has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NeuroSearch improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NeuroSearch's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NeuroSearch has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NeuroSearch's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NeuroSearch's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NeuroSearch is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NeuroSearch has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NeuroSearch's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NeuroSearch has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NeuroSearch Company Filings, last reported 3 months ago.

DB:NRS Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 70.52 0.00 71.24
2018-06-30 70.30 0.00 70.40
2018-03-31 70.30 0.00 70.40
2017-12-31 73.35 0.00 74.08
2017-06-30 68.80 0.00 65.90
2017-03-31 68.80 0.00 65.90
2016-12-31 71.38 0.00 74.44
2016-09-30 71.38 0.00 74.45
2016-06-30 72.00 0.00 77.40
2016-03-31 72.00 0.00 77.40
2015-12-31 72.40 0.00 77.97
2015-06-30 75.20 0.00 80.20
2015-03-31 75.20 0.00 80.20
2014-12-31 77.71 0.00 83.40
2014-06-30 78.20 0.00 84.10
2014-03-31 78.20 0.00 84.10
2013-12-31 87.95 0.00 88.85
2013-09-30 87.60 13.70 94.30
2013-06-30 98.60 83.60 62.80
2013-03-31 77.80 120.80 68.20
2012-12-31 81.05 102.17 81.43
2012-09-30 -79.00 0.00 46.60
2012-06-30 -60.90 0.00 88.00
  • NeuroSearch has no debt.
  • NeuroSearch had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NeuroSearch has sufficient cash runway for more than 3 years based on current free cash flow.
  • NeuroSearch has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -14.6% each year.
X
Financial health checks
We assess NeuroSearch's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NeuroSearch has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NeuroSearch's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NeuroSearch dividends.
If you bought €2,000 of NeuroSearch shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NeuroSearch's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NeuroSearch's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NRS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NeuroSearch has not reported any payouts.
  • Unable to verify if NeuroSearch's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NeuroSearch's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NeuroSearch has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NeuroSearch's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NeuroSearch afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NeuroSearch has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NeuroSearch's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Allan Andersen
COMPENSATION DKK75,000
AGE 73
TENURE AS CEO 5.3 years
CEO Bio

Mr. Allan Andersen, DVM, has been the Chief Executive Officer of Neurosearch A/S since December 1, 2013. He serves as the Chief Executive Officer and Director at NeuroSearch Sweden AB. Mr. Andersen also serves as the President of Freja Ejendomme A/S. He served as the Chief Executive Officer of AA Consult ApS. He served as the Chairman of Nordicom A/S. He served as the Chairman of Neurosearch A/S until December 1, 2013. He served as the Chairman of Udviklingsselskabet af 01.08. 1975 A/S since April 27, 2010. He served as the Deputy Chairman of Glunz & Jensen A/S. He has been a Director at Neurosearch A/S since 1990 and NeuroSearch AB since 1989. He has been a Director of Connectia A/S since 2006. He has been a Director of Schaumann Properties A/S since April 27, 2010. He serves as a Director of Freja ejendomme AS, PBI-Holding and Ringsted A/S. Mr. Andersen serves as a Director of Actics Ltd. He served as Director of Glunz & Jensen A/S from 1991 to 2005. Mr. Andersen served as a Director of Greater Europe Deep Value Fund Ltd, Greater Europe Deep Value Fund II Ltd., Greater Europe Fund Ltd, GEF SPV Ltd., AA Consult ApS and DVF SPV Ltd. He was Chairman at Park Street Nordicom A/S.

CEO Compensation
  • Insufficient data for Allan to compare compensation growth.
  • Allan's remuneration is lower than average for companies of similar size in Germany.
Management Team

Allan Andersen

TITLE
CEO & Director
COMPENSATION
DKK75K
AGE
73
TENURE
5.3 yrs

Anita Milland

TITLE
Vice President of Finance & Administration
Board of Directors Tenure

Average tenure and age of the NeuroSearch board of directors in years:

0.6
Average Tenure
44
Average Age
  • The average tenure for the NeuroSearch board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mikkel Kæregaard

TITLE
Chairman of the Board
AGE
44
TENURE
0.6 yrs

Allan Andersen

TITLE
CEO & Director
COMPENSATION
DKK75K
AGE
73
TENURE
29.9 yrs

Morten Mathiesen

TITLE
Vice Chairman
AGE
43
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NeuroSearch's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NeuroSearch has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NeuroSearch A/S does not have significant operations. Previously, the company was engaged in the research and development of drugs in the CNS segment. The company was founded in 1989 and is based in Hvidovre, Denmark.

Details
Name: NeuroSearch A/S
NRS
Exchange: DB
Founded: 1989
DKK14,442,860
24,288,001
Website: http://www.neurosearch.com
Address: NeuroSearch A/S
Hammerholmen 47,
Hvidovre,
2650,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE NEUR Common Stock OMX Nordic Exchange Copenhagen DK DKK 17. Jun 1996
DB NRS Common Stock Deutsche Boerse AG DE EUR 17. Jun 1996
LSE 0FE8 Common Stock London Stock Exchange GB DKK 17. Jun 1996
BATS-CHIXE NEURC Common Stock BATS 'Chi-X Europe' GB DKK 17. Jun 1996
Number of employees
Current staff
Staff numbers
1
NeuroSearch employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:45
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.